Form 4: Longboard Pharmaceuticals Executive Exercises Options and RSUs in Merger

An SEC Form 4 filing details the conversion of Longboard Pharmaceuticals executive Randall Kaye's stock options and restricted stock units into cash following the company's merger with a Lundbeck subsidiary.

Summary

• This document is an SEC Form 4 filing detailing changes in beneficial ownership for Randall Kaye, an Executive Vice President & CMO at Longboard Pharmaceuticals.
• The filing reports the conversion of Kaye's common stock, employee stock options, and restricted stock units (RSUs) into cash as a result of Longboard's merger with a subsidiary of H. Lundbeck A/S.
• The merger, completed on December 2, 2024, involved a tender offer where shares were acquired for $60.00 each.
• All outstanding stock options, both vested and unvested, were accelerated and converted into cash based on the difference between the $60.00 merger price and the option's exercise price.
• All RSUs, including retention RSUs, were also converted into cash at $60.00 per share, with retention RSUs subject to their original vesting schedule.
• Kaye's holdings of 30,554 common shares were converted to cash at $60 per share.
• Kaye's employee stock options for 175,946 shares at $6, 96,300 shares at $4.35, and 107,560 shares at $19.32 were converted to cash.
• Kaye's 17,920 RSUs and 9,500 retention RSUs were converted to cash.

Sentiment

Score: 7

Explanation: The document is a routine filing related to a merger, which is generally a positive event for shareholders. The sentiment is neutral to positive as it reflects the completion of a transaction that provides liquidity to shareholders and option holders.

Future Outlook

The document does not contain any forward-looking statements beyond the completion of the merger.

Industry Context

This filing reflects a common outcome of a merger or acquisition, where outstanding equity awards are converted to cash. This is a standard practice in corporate transactions to ensure fair treatment of employees and executives.

Comparison to Industry Standards

• The conversion of stock options and RSUs to cash upon a merger is a standard practice in the pharmaceutical industry, similar to acquisitions of companies like Immunomedics by Gilead or Alexion by AstraZeneca.
• The $60 per share merger consideration is a typical method of valuation in acquisitions, similar to the per-share price paid in the acquisition of Biohaven by Pfizer.
• The treatment of retention RSUs with continued vesting schedules is also a common practice to ensure key employees remain with the company post-acquisition, similar to retention agreements in other pharmaceutical mergers.

Stakeholder Impact

• Shareholders received $60.00 per share in cash.
• Employees and executives with stock options and RSUs received cash payments based on the merger terms.
• The merger resulted in Longboard becoming an indirect wholly owned subsidiary of H. Lundbeck A/S.

Key Dates

Keywords

Merger, SEC Form 4, Stock Options, Restricted Stock Units, Beneficial Ownership, Longboard Pharmaceuticals, Lundbeck, Acquisition